Information Provided By:
Fly News Breaks for February 28, 2018
GBT
Feb 28, 2018 | 10:06 EDT
Cantor Fitzgerald analyst Elemer Piros raised his price target for Global Blood Therapeutics to $72 citing increased confidence going into the Phase 3 Part A study with voxelotor in patients with sickle cell disease. The analyst says that while the company did not host a Q4 earnings conference call, he did not find any surprises in the annual filing. Piros raised his probability of success for the sickle cell disease program to 70% from 55% and reiterates an Overweight rating on Global Blood shares.
News For GBT From the Last 2 Days
There are no results for your query GBT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.